Rosetta Grants Prometheus Rights to Sell Suite of microRNA Diagnostics in US
April 16, 2009
Rosetta Grants Prometheus Rights to Sell Suite of microRNA Diagnostics in US
In doing so, Rosetta is meeting its objective of finding commercialization partners for its existing products as it shifts its focus onto tests that screen for, rather than diagnose, disease.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Three RNAi, miRNA Firms Record Strong Gains in Stock Value Since the End of 2008
April 30, 2009 / Gene Silencing News - Rosetta, Prometheus Close Deal for miRNA Dx Market Rights
April 30, 2009 / Gene Silencing News - Exiqon Exec Says Impact of miRNA Dx Will Take Time, Company Offers Peek at Other Tests
March 5, 2009 / Gene Silencing News - Rosetta Genomics Could Debut Colon Cancer Screen in US This Year, Shifts Focus from Dxs
March 26, 2009 / Gene Silencing News - Rosetta Genomics Publishes Data on Lung Cancer Test
March 10, 2009 / GenomeWeb Daily News